Article

OBJECTIVE: To examine the effect of participating in a 12-week supervised
exercise training (ET) program on physical activity and body composition in
patients with idiopathic pulmonary fibrosis (IPF).
DESIGN: Randomized controlled
trial assessing physical activity and body composition at baseline, after 12-week
intervention, and at 11 months follow-up.
SETTING: Outpatient hospital.
PARTICIPANTS: Patients with IPF (N=34; mean age, 68+/-8y) recruited for this
study; 32 patients completed the 12-week intervention (ET group: n=15; control
group: n=17) and 28 patients (14 in each group) reassessed at 11-month follow-up
from baseline. INTERVENTIONS: Participation in a 12-week supervised ET program or
regular medical treatment. MAIN OUTCOME MEASURES: Changes in physical activity
levels as measured by the International Physical Activity Questionnaire. RESULTS:
After the 12-week intervention, physical activity levels were significantly
increased in the ET group whereas the control group showed a trend toward
deterioration (median difference between the groups, 2164MET-min/wk
[interquartile range, 1576MET-min/wk]; MET = metabolic equivalent; P<.001). Body
composition was also significantly improved in the ET group, whereas the control
group showed an opposite trend. At 11-month follow-up, no significant differences
were observed between the 2 groups in all variables. The ET group lost most of
the achieved improvements in the outcomes and returned to near baseline levels,
whereas the control group showed a trend toward worsened outcomes. CONCLUSIONS:
Physical activity and body composition in patients with IPF were improved after a
12-week supervised ET program, although the benefits were not sustained at
11-month follow-up. These results may support the efficacy of participation in
supervised ET to improve physical activity and body composition in patients with
IPF; however, maintenance strategies are warranted to preserve the improved
outcomes.
CI - Copyright (c) 2016 American Congress of Rehabilitation Medicine. Published by
Elsevier Inc. All rights reserved.

Langue : ANGLAIS